TABLE 1.
Percent (%) prevalence of ocular viral infections and glaucoma (G) in various reported cohorts
| HSV (G) | VZV (G) | CMV (G) | RUBV (G) | DENV (G) | ZIKV (G) | CHIKV (G) | WNV (G) | EBOV (G) | MUVc (G) | Overall glaucoma incidence (%) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shirahama et al. (17) (Japan) n = 170 |
18 (16) | 38 (9) | 44 (72) | − | − | − | − | − | − | − | 37.64 |
| Hoeksema et al. (18) (The Netherlands) n = 73 (100% unilateral) |
74 (17) | 26 (11) | − | − | − | − | − | − | − | 15 | |
| Shimizu et al. (19) (Japan) n = 105 (141 eyes) |
6.6 (6.6) | 1.9 (1–9) | − | − | − | − | − | − | − | − | 9.73 |
| Pohlmann et al. (20) (Germany) n = 270 (all open angle) |
29 (6.49) | 17 (6.66) | 21 (56.14) | 29 (14.28) | − | − | − | − | − | 5 (7.14) | 19 |
| Wensing et al. (21) (The Netherlands) n = 106 |
36.8 (22) | 10.6 (23) | − | 53.77 (17) | − | − | − | − | − | − | 21 |
| Miserocchi et al. (22) (USA) n = 64 (68 eyes) |
62.5 (23) | 37.5 (25) | − | − | − | − | − | − | − | − | 51 |
| Miserocchi et al. (24) (Italy) n = 241 |
78.4 (38.1) | 18.7 (27) | 2.9 (28.6) | − | − | − | − | − | − | − | 38 |
| Khieu et al. (10) (Thailand) n = 31 (PCR confirmed) | 10 (0) | 3 (0) | 19 (17) | − | − | − | − | − | − | − | 41.93 |
| van Boxtel et al. (25) (The Netherlands) n = 7 (case series) |
− | − | 100 (100) | − | − | − | − | − | − | − | 100 |
| Leleu et al. (26) (France) n = 38 (PCR or GWC confirmed) |
− | − | 100 (50) | − | − | − | − | − | − | − | 50 |
| Engelhard et al. (27) (USA) n = 77 (92 eyes) |
51.326 (NA)d | 43.6 (NA) | 2.56 (NA) | − | − | − | − | − | − | − | 23.37 |
|
aTugal-Tutkun et al. (28) (Turkey) n = 111 (114 eyes) |
− | − | − | − | − | − | − | − | − | − | 1.8 |
| Sungur et al. (29) (Turkey) n = 76 |
76 (12) | 24 (2) | − | − | − | − | − | − | − | − | 13.1 |
|
bYepez et al. (7) (South America) n = 43 |
− | − | − | − | − | NA (12) | − | − | − | − | 12 |
| Groen-Hakan et al. (30) (The Netherlands) n = 127 (144 eyes) |
− | − | − | 38 (28) | − | − | − | − | − | − | 28 |
| Thean et al. (31) (Australia) n = 34 | − | 100 (56) | − | − | − | − | − | − | − | − | 56 |
| Chee and Jap (32) (Singapore) n = 102 (103 eyes) |
− | − | 38.83 (12.62) | − | − | − | − | − | − | − | 25.24 |
| Fan et al. (33) n = 60 |
− | 41.66 (41.66) | 21.66 (21.66) | − | − | − | − | − | − | − | 100 |
| de Visser et al. (34) (The Netherlands) n = 30 |
− | − | − | 100 (23.33) | − | − | − | − | − | − | 23.3 |
| Shantha et al. (35) n = 23 (pediatric cohort) |
− | − | − | − | − | − | − | − | 56.5 (6.5) | − | 6.5 |
a
No PCR or Goldman-Witmer coefficient (GWC) analysis data were reported. Diagnosis was established based on clinical presentation.
b
CZS cohort.
c
MUV, multiple viruses.
d
NA, not applicable.